Quick Answer
KESTRA MEDICAL TECHNOLOGIES, LTD. reported R&D Expense of $15.65 million for fiscal year 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $15.65M | +1.0% |
| 2024 | $15.49M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $4.97M | +48.3% | +1.9% |
| October 31, 2025 | $4.88M | +39.0% | +21.9% |
| July 31, 2025 | $4.00M | +17.5% | +19.3% |
| January 31, 2025 | $3.35M | — | -4.4% |
| October 31, 2024 | $3.51M | — | +3.1% |
| July 31, 2024 | $3.40M | — | — |
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +1.0% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, KESTRA MEDICAL TECHNOLOGIES, LTD.’s r&d expense has grown by 1.0% (from $15.49 million to $15.65 million).
- The most recent figure is from KESTRA MEDICAL TECHNOLOGIES, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: